ASCO 2025 | STARGLO 2-year follow-up: durability of responses in patients with DLBCL receiving Glofitamab-GemOx

The STARGLO trial was a registrational trial looking at Glofitamab-GemOx versus Rituximab with GemOx for transplant-ineligible patients with relapsed large cell lymphoma. At the ASCO meeting in 2025 as well as in the European meetings we’re now seeing the two-year follow-up on this trial. The initial primary endpoint was met last year, presented as a plenary abstract at EHA, demonstrating a statistically significant and clinically meaningful overall survival benefit for patients randomized to Glofitamab GemOx versus R-GemOx. 

With two-year follow-up now, we’re seeing durability, particularly in the Glofitamab GemOx arm, where we’re seeing that with a median follow-up of 24 months, we’ve got a median overall survival not yet reached for the Glofitamab-GemOx arm. Very importantly, with a landmark analysis of patients performed, looking at patients who’d achieved remission on their end-of-treatment PET scan, we’re now seeing that 89% of them are still alive and quite remarkably 82% of them are free from progression. Historically we’ve always believed that patients in order to achieve a cure in the relapsed large cell lymphoma setting need to have a cellular therapy to get there but with the STARGLO data now out to two years we’re seeing durability of responses indicating that there are a proportion of these patients likely to have a durable remission and dare I say cure and addressing a major unmet clinical need.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.